ENDOMETRIAL TRANSITIONAL CELL CARCINOMA

Clinical trials for ENDOMETRIAL TRANSITIONAL CELL CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new ENDOMETRIAL TRANSITIONAL CELL CARCINOMA trials appear

Sign up with your email to follow new studies for ENDOMETRIAL TRANSITIONAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Major trial aims to tame dozens of rare, neglected cancers with immune power combo

Disease control Ongoing

This large national trial is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control over 50 different types of rare cancers that have few or no standard treatment options. It enrolled over 800 adults whose rare cancers had progressed …

Matched conditions: ENDOMETRIAL TRANSITIONAL CELL CARCINOMA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 30, 2026 14:32 UTC

ENDOMETRIAL TRANSITIONAL CELL CARCINOMA

Get alerted when new ENDOMETRIAL TRANSITIONAL CELL CARCINOMA trials appear

Major trial aims to tame dozens of rare, neglected cancers with immune power combo